Scientific journal
International Journal of Applied and fundamental research
ISSN 1996-3955
ИФ РИНЦ = 0,593

Personal portfolio

2 2 2 2
2 Institute of Bioorganic Chemistry, RAS
Immunotherapy is currently emerging mode of breast cancer therapy as efficacy of traditional therapies seems to reach plateau nowadays. First transplanted generation from non-SPF spontaneous BLRB mammary adenocarcinoma (MAC) were used as appropriate mouse model to examine whether a single local interleukin-2 (IL-2) treatment is efficient against mammary cancer. We showed that survival dynamics of syngeneic recipients with early emerging transplanted mammary cancer (short subclinical period) could be significantly improved by a single IL-2 treatment (2.5 x106 IU per mouse) applied locally two weeks after MAC cell inoculation. However, the same IL-2 therapy mode applied to later emerging tumors (long subclinical period) of the same average size of 5 mm as late as eighth week after tumor cell inoculation notably shortened the survival of tumorbearing mice. Finally, both the fundamental significance and applied implications of biphasic IL-2 effect on mammary cancer growth was shown and discussed.
breast cancer
mouse model
prognostic factors
immunotherapy
interleukin-2
roncoleukin
BC
breast cancer
in women; MC
mammary cancer
in mice; MAC
mammary adenocarcinoma; interleukin-2
IL-2
1. Blidaru A., Bordea C.I., Viisoreanu C.G., Bordea M., Iliescu I., Dutescu D., Radu F., Dragoescu H. (1998) Rom J Physiol, l 35, 127-134
2. Kiessling R., Wasserman K., Horiguchi S., Kono K., Sjoberg J., Pisa P., Petersson M. (1999) Cancer Immunol Immunother, 48, 353-362
3. Hadden J.W. (1999) Int J Immunopharmacol, 21, 79-101
4. Pockaj B.A., Basu G.D., Pathangey L.B., Gray R.J., Hernandez J.L., Gendler S.J., Mukherjee P. (2004) Ann Surg Oncol, 11, 328-339
5. Kang D.H., Weaver M.T., Park N.J., Smith B., McArdle T., Carpenter J. (2009) Nurs Res, 58, 105-114
6. Venetsanakos E., Beckman I., Bradley J., Skinner J.M. (1997) Br J Cancer, 5, 1826-1830
7. Wong P.Y., Staren E.D., Tereshkova N., Braun D.P. (1998) J Surg Res, 76, 95-103
8. Bernsen M.R., Tang J.-W., Everse L.A., Koten J.-W., Den Otter W. (1999) Cancer Treat Rev, 25, 73-82
9. Kroemer G., Toribio M.L., Martinez C. (1991) New Biol, 3, 219-229
10. Overwijk W.W., Schluns K.S. (2009) Clin Immunol, 132, 153-165
11. Disis M.L., Bernhard H., Jaffee E.M. (2009) Lancet, 373, 673-683
12. Nicolini A., Carpi A. (2009) Med Res Rev, 29, 436-471
13. Moiseyeva E (2005) Utrecht University, The Netherlands 191 pp, http://igitur-archive.library.uu.nl/dissertations/2005-1130-200033/index.htm
14. Grande C., Firvida J.L., Navas V., Casal J. (2006) Anticancer Drugs, 17, 1-12
15. Nicolini A., Carpi A., Rossi G. (2005) J Immunother, 28, 276-279
16. Malek T.R. (2008) Annu Rev Immunol, 26, 453-479
17. Montero E., Alonso L., Perez R., Lage A. (2007) Ann N Y Acad Sci, 1107, 239-250
18. Dai Z., Konieczny B.T., Lakkis F.G. (2000) J Immunol, 165, 3031-3036
19. Everse L.A., Bernsen M.R., Dullens H.F., Den Otter W. (1996) J Exp Ther Oncol 1, 231-236
20. Shrikant P., Mescher M.F. (2002) J Immunol, 169, 1753 - 1759
21. Moiseeva E.V., Merkulova I.B., Bijleveld C., Koten J.W., Miroshnikov A.I., Den Otter W. (2003) Cancer Immunol Immunother, 52, 487-496
22. Characiejus D., Pasukoniene V., Kazlauskaite N., Valuckas K.P., Petraitis T., Mauricas M., Den Otter W. (2002) Anticancer Res, 22, 3679-3683
23. Harris J.R., Morrow M., Bonadonna G. (1993) In.: Cancer Principl Pract Oncol 1264-1332
24. Jackaman C., Bundell C.S., Kinnear B.F., Smith A.M., Filion P., van Hagen D., Robinson B.W., Nelson D.J. (2003) J Immunol, 171, 5051-5063
25. Molchanov O., Karelin M., Zharinov G. (2002) Cytokin Inflam, 1, 38-47
26. Burke H.B. (2004) J Natl Cancer Inst, 96, 1408-1409
27. Friberg S., Mattson S. (1997) J Surg Oncol, 65, 284-297
28. Kedar E., Klein E. (1992) Adv Cancer Res, 59, 245-322